RHYTHM PHARMACEUTICALS, INC. (RYTM) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $69.00K; Additional Paid in CapitalUSD $1.56B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-912.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $69.00K; Additional Paid in CapitalUSD $1.53B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $444.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $67.00K; Additional Paid in CapitalUSD $1.49B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-796.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $67.00K; Additional Paid in CapitalUSD $1.45B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-926.00K.
RHYTHM PHARMACEUTICALS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $69.00K | $1.56B | $-912.00K | $-1.46B | $102.98M | (m) | 3 month · $26.06M | 3 month · $1.06M |
| 2026-03-31 | $0.00 | $69.00K | $1.53B | $444.00K | $-1.41B | $122.91M | (m) | 3 month · $23.10M | 3 month · $1.10M |
| 2025-12-31 | $0.00 | $67.00K | $1.49B | $-796.00K | $-1.35B | $139.07M | (m) | 12 month · $66.82M | 12 month · $5.38M |
| 2025-09-30 | (m) | $67.00K | $1.45B | $-926.00K | $-1.30B | $148.82M | 3 month · $12.60M 9 month · $700.00K | 3 month · $18.81M | 3 month · $1.38M |
| 2025-06-30 | (m) | $64.00K | $1.24B | $-2.25M | $-1.25B | $-11.91M | (m) | 3 month · $15.88M | 3 month · $1.35M |
| 2025-03-31 | (m) | $62.00K | $1.22B | $-51.00K | $-1.20B | $18.95M | 3 month · $739.00K | 3 month · $12.86M | 3 month · $1.32M |
| 2024-12-31 | (m) | $61.00K | $1.18B | $-39.00K | $-1.16B | $21.73M | (m) | 12 month · $39.68M | 12 month · $3.97M |
| 2024-09-30 | (m) | $61.00K | $1.12B | $-604.00K | $-1.11B | $11.21M | (m) | 3 month · $11.00M | 3 month · $1.33M |
| 2024-06-30 | (m) | $60.00K | $1.11B | $-617.00K | $-1.07B | $39.34M | (m) | 3 month · $10.36M | 3 month · $1.30M |
| 2024-03-31 | (m) | $60.00K | $1.10B | $-181.00K | $-1.04B | $61.58M | (m) | 3 month · $7.77M | (m) |
| 2023-12-31 | (m) | $59.00K | $1.06B | $134.00K | $-894.74M | $169.76M | (m) | 12 month · $32.55M | (m) |
| 2023-09-30 | (m) | $59.00K | $1.05B | $-113.00K | $-853.10M | $197.47M | (m) | 3 month · $8.61M | (m) |
| 2023-06-30 | (m) | $57.00K | $991.18M | $-14.00K | $-808.94M | $182.28M | (m) | 3 month · $8.89M | (m) |
| 2023-03-31 | (m) | $56.00K | $981.95M | $-6.00K | $-762.24M | $219.76M | (m) | 3 month · $6.38M | (m) |
| 2022-12-31 | (m) | $56.00K | $974.36M | $-92.00K | $-710.06M | $264.26M | (m) | 12 month · $19.83M | (m) |
| 2022-09-30 | (m) | $56.00K | $949.04M | $-339.00K | $-667.57M | $281.19M | (m) | 3 month · $4.80M | (m) |
| 2022-06-30 | (m) | $50.00K | $823.19M | $-906.00K | $-626.70M | $195.63M | (m) | 3 month · $5.14M | (m) |
| 2022-03-31 | (m) | $50.00K | $818.05M | $-629.00K | $-581.70M | $235.77M | (m) | 3 month · $4.61M | (m) |
| 2021-12-31 | (m) | $50.00K | $813.04M | $-1.00K | $-528.94M | $284.15M | (m) | 12 month · $20.80M | (m) |
| 2021-09-30 | (m) | $50.00K | $808.26M | $21.00K | $-486.07M | $322.26M | (m) | 3 month · $5.27M | (m) |
| 2021-06-30 | (m) | $50.00K | $802.58M | $21.00K | $-450.97M | $351.69M | (m) | 3 month · $5.67M | (m) |
| 2021-03-31 | (m) | $50.00K | $796.53M | $-58.00K | $-415.58M | $380.95M | (m) | 3 month · $5.19M | (m) |
| 2020-12-31 | (m) | $44.00K | $625.76M | $49.00K | $-459.33M | $166.53M | (m) | 12 month · $17.45M | (m) |
| 2020-09-30 | (m) | $44.00K | $621.09M | $238.00K | $-424.43M | $196.94M | (m) | 3 month · $4.70M | (m) |
| 2020-06-30 | (m) | $44.00K | $615.69M | $630.00K | $-390.61M | $225.75M | (m) | 3 month · $3.03M | (m) |
| 2020-03-31 | (m) | $44.00K | $612.55M | (m) | $-359.50M | $253.10M | (m) | 3 month · $5.47M | (m) |
| 2019-12-31 | (m) | $44.00K | $606.31M | (m) | $-325.33M | $281.02M | (m) | 12 month · $11.88M | (m) |
| 2019-09-30 | (m) | $35.00K | $441.45M | (m) | $-292.38M | $149.12M | (m) | 3 month · $3.04M | (m) |
| 2019-06-30 | (m) | $34.00K | $437.81M | (m) | $-256.37M | $181.47M | (m) | 3 month · $3.27M | (m) |
| 2019-03-31 | (m) | $34.00K | $434.03M | (m) | $-213.58M | $220.49M | (m) | 3 month · $2.64M | (m) |
| 2018-12-31 | (m) | $34.00K | $430.82M | (m) | $-184.60M | $246.26M | 12 month · $162.88M | 9 month · $5.43M 12 month · $6.39M | (m) |
| 2018-09-30 | (m) | $34.00K | $428.70M | (m) | $-159.09M | $269.64M | 3 month · $135.00K | 3 month · $1.89M | (m) |
| 2018-06-30 | (m) | $34.00K | $425.41M | (m) | $-141.12M | $284.32M | (m) | 3 month · $1.52M | (m) |
| 2018-03-31 | (m) | $27.00K | $260.34M | (m) | $-126.71M | $133.66M | (m) | 3 month · $958.00K | (m) |
| 2017-12-31 | (m) | $27.00K | $255.01M | (m) | $-110.25M | $144.79M | 12 month · $108.00K | 12 month · $2.28M | (m) |
| 2017-09-30 | $79.00K | $2.00K | $47.78M | (m) | $-99.72M | $-51.86M | 9 month · $108.00K | 9 month · $1.57M | (m) |
| 2016-12-31 | (m) | $10.00K | $43.83M | (m) | $-76.54M | $-32.70M | (m) | 12 month · $1.17M | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | $-8.00M | (m) | 12 month · $298.00K | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | $-358.00K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |